Development of PI3Kγ selective inhibitors: the strategies and application

被引:0
|
作者
Dong-yan Gu
Meng-meng Zhang
Jia Li
Yu-bo Zhou
Rong Sheng
机构
[1] Zhejiang University,College of Pharmaceutical Sciences
[2] State Key Laboratory of Drug Research,National Center for Drug Screening
[3] Shanghai Institute of Materia Medica,undefined
[4] Chinese Academy of Sciences,undefined
来源
关键词
PI3K; PI3Kγ inhibitors; isoform selectivity; drug development; rational drug design;
D O I
暂无
中图分类号
学科分类号
摘要
The γ isoform of Class I PI3Ks (PI3Kγ) is primarily found in leukocytes and is essential for the function of myeloid cells, as it regulates the migration, differentiation, and activation of myeloid-lineage immune cells. Thus, PI3Kγ has been identified as a promising drug target for the treatment of inflammation, autoimmune disease, and immuno-oncology. Due to the high incidence of serious adverse events (AEs) associated with PI3K inhibitors, in the development of PI3Kγ inhibitors, isoform selectivity was deemed crucial. In this review, an overview of the development of PI3Kγ selective inhibitors in the past years is provided. The isoform selectivity of related drugs was achieved by different strategies, including inducing a specificity pocket by a propeller-shape structure, targeting steric differences in the solvent channel, and modulating the conformation of the Asp-Phe-Gly DFG motif, which have been demonstrated feasible by several successful cases. The insights in this manuscript may provide a potential direction for rational drug design and accelerate the discovery of PI3Kγ selective inhibitors.
引用
收藏
页码:238 / 247
页数:9
相关论文
共 50 条
  • [21] Highly delta selective quinazolinone PI3K inhibitors
    Treiberg, Jennifer
    Chandrasekhar, Jayaraman
    Ip, Carmen
    Koditek, David
    Lepist, Eve-Irene
    McGrath, Mary
    Mwangi, Judy
    Perreault, Stephane
    Somoza, John
    Steiner, Bart
    Therrien, Joseph
    Villasenor, Armando
    Wise, Sarah
    Wong, Belinda
    Phillips, Gary
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2018, 255
  • [22] Biomarker evaluation In phase I clinical trials of selective PI3K and PI3K/mTOR inhibitors
    Spoerke, Jill
    O'Brien, Carol
    Wu, Jenny
    Desai, Rupal
    Patel, Rajesh
    Raja, Rajiv
    Koeppen, Hartmut
    Amler, Lukas
    Hampton, Garret
    Yan, Yibing
    Lackner, Mark R.
    [J]. CANCER RESEARCH, 2012, 72
  • [23] Biomarker evaluation in phase I clinical trials of selective PI3K and PI3k/mTOR inhibitors
    Spoerke, Jill
    Desai, Rupal
    Patel, Rajesh
    Fredrickson, Jill
    Wang, Yulei
    Levy, Gallia
    Gendreau, Steve
    Lauchle, Jennifer
    Derynck, Mika
    Raja, Rajiv
    Koeppen, Hartmut
    Hampton, Garret
    Yan, Yibing
    Lackner, Mark R.
    [J]. CANCER RESEARCH, 2013, 73 (08)
  • [24] Development of isoform selective PI3-kinase inhibitors as pharmacological tools for elucidating the PI3K pathway
    Bruce, Ian
    Akhlaq, Mohammed
    Bloomfield, Graham C.
    Budd, Emma
    Cox, Brian
    Cuenoud, Bernard
    Finan, Peter
    Gedeck, Peter
    Hatto, Julia
    Hayler, Judy F.
    Head, Denise
    Keller, Thomas
    Kirman, Louise
    Leblanc, Catherine
    Le Grand, Darren
    McCarthy, Clive
    O'Connor, Desmond
    Owen, Charles
    Oza, Mrinalini S.
    Pilgrim, Gaynor
    Press, Nicola E.
    Sviridenko, Lilya
    Whitehead, Lewis
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2012, 22 (17) : 5445 - 5450
  • [25] Challenges for the Clinical Development of PI3K Inhibitors: Strategies to Improve Their Impact in Solid Tumors
    Hanker, Ariella B.
    Kaklamani, Virginia
    Arteaga, Carlos L.
    [J]. CANCER DISCOVERY, 2019, 9 (04) : 482 - 491
  • [26] Pharmacodynamic biomarker evaluation in phase I clinical trials of selective PI3K and PI3K/mTOR inhibitors
    Nakanishi, Yoshito
    Spoerke, Jill M.
    Derynck, Mika
    Lauchle, Jennifer O.
    Koeppen, Hartmut
    Fredrickson, Jill
    Ware, Joseph
    Hampton, Garret
    Yan, Yibing
    Lackner, Mark R.
    [J]. MOLECULAR CANCER THERAPEUTICS, 2015, 14 (07)
  • [27] Isoform-Selective PI3K Inhibitors for Various Diseases
    Bheemanaboina, Rammohan R. Y.
    [J]. CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2020, 20 (12) : 1074 - 1092
  • [28] Discovery of fluoroquinolone derivatives as potent, selective inhibitors of PI3Kγ
    Sha, Shao
    Han, Hong-Wei
    Gao, Fei
    Liu, Tian-Bao
    Li, Zhen
    Xu, Chi
    Zhong, Wei-Qing
    Zhu, Hai-Liang
    [J]. MEDCHEMCOMM, 2015, 6 (11) : 2029 - 2035
  • [29] Synthesis and SAR study of potent and selective PI3Kδ inhibitors
    Bui, Minna
    Hao, Xiaolin
    Shin, Youngsook
    Cardozo, Mario
    He, Xiao
    Henne, Kirk
    Suchomel, Julia
    McCarter, John
    Mcgee, Lawrence R.
    Miguel, Tisha San
    Medina, Julio C.
    Mohn, Deanna
    Tran, Thuy
    Wannberg, Sharon
    Wong, Jamie
    Wong, Simon
    Zalameda, Leeanne
    Metz, Daniela
    Cushing, Timothy D.
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2015, 25 (05) : 1104 - 1109
  • [30] Discovery of novel class of alpha selective PI3K inhibitors
    Garland, Keira
    Hanan, Emily
    Staben, Steven
    Braun, Marie-Gabrielle
    Edgar, Kyle
    Endres, Nick
    Friedman, Lori
    Nguyen, Amanda
    Pang, Jodie
    Purkey, Hans
    Salphati, Laurent
    Schmidt, Stephen
    Song, Kyung
    Ultsch, Mark
    Jaochico, Allan
    Chan, Connie
    Eigenbrot, Charles
    MacLeod, Calum
    Jackson, Philip
    Narukulla, Raman
    Knight, Jamie
    Yeap, Kuen
    Messick, Kristen
    Valle, Nicole
    Heald, Robert
    Nannini, Michelle
    Hamilton, Pat
    Clausen, Saundra
    Young, Amy
    Sampath, Deepak
    Hong, Rebecca
    Lee, Man-Ling
    Blench, Toby
    Elliott, Richard
    Lu, Aijun
    Gu, Xiao-Hu
    Xin, Jianfeng
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2017, 254